An observational study in Acute Lymphoblastic Leukemia ALL, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris — 8 open to participants now, 10 under way, 3 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Assistance Publique - Hôpitaux de Paris.
Among the 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is one of 6 observational ones, and was the 18th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →8 of the 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 1–25
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–59
By country, each count listing its studies:
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: Up to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 5
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 205 is above the median of 107 across 401 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 161 across the 12 interventional studies, 253 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350994Assistance Publique - Hôpitaux de ParisEarly Assessment of Cardiac Function After Treatment With CAR-T Cells | 2026-12 |
| NCT05310591Assistance Publique - Hôpitaux de ParisCombination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Minimal residual disease (MRD) monitoring is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Currently, MRD assessment relies mainly on cellular DNA obtained from bone marrow aspirates. Although highly informative, this approach has limitations, including the need for invasive procedures and the fact that it reflects only the bone marrow compartment.
Tumor cells release fragments of genomic DNA into the bloodstream, known as circulating cell-free DNA (cfDNA). In solid tumors, cfDNA analysis has emerged as a valuable non-invasive biomarker for disease monitoring and treatment response. Recent studies have shown that cfDNA is detectable in pediatric ALL.
This study aims to investigate whether plasma cfDNA analysis could represent an alternative or complementary approach to bone marrow-based MRD assessment. cfDNA may better reflect the global tumor burden across the entire body and allow more frequent longitudinal monitoring during treatment.
The primary objective is to assess the correlation between MRD measured in plasma cfDNA and MRD measured in bone marrow cellular DNA at two key timepoints of treatment: the end of induction (Day 29) and the end of consolidation (Day 71-78).
Secondary objectives include evaluating the correlation between peripheral blood cellular DNA and bone marrow MRD, describing clonal evolution using cfDNA throughout treatment and follow-up, exploring the concordance of genomic alterations detected in cfDNA and other biological compartments, assessing the prognostic value of cfDNA MRD for relapse risk and event-free survival, and characterizing cfDNA fragmentome and methylome signatures in patients compared with healthy controls.
The study will include children and adolescents with newly diagnosed ALL treated at two AP-HP pediatric hematology centers, as well as a control cohort of healthy children undergoing HLA typing for sibling stem cell transplant.
Study population Children and adolescents with newly diagnosed acute lymphoblastic leukemia treated in participating pediatric hematology centers, as well as healthy pediatric siblings undergoing HLA typing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ALL population
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children and adolescents (\<18 years) with newly diagnosed B-cell or T-cell acute lymphoblastic leukemia without BCR::ABL1 rearrangement (and without KMT2A rearrangement in infants), included before initiation of steroid therapy or chemotherapy.
Other: Biological sample collection
Children and adolescents (\<18 years) undergoing blood sampling for HLA typing for a sibling with leukemia.
Other: Biological sample collection
Additional peripheral blood samples will be collected during treatment and follow-up for cell-free DNA analysis. Residual samples from bone marrow and cerebrospinal fluid collected as part of standard clinical care will also be analyzed.
Correlation between plasma cfDNA MRD and bone marrow MRD
Pearson correlation coefficient between minimal residual disease (MRD) measured in plasma circulating cell-free DNA and MRD measured in bone marrow cellular DNA. Analyses will be performed according to the type of molecular target used for MRD detection (IG/TCR rearrangements, genomic breakpoints, or pathogenic variants). End of induction (Day 29) and end of consolidation (Day 71-78)
Time frame: Up to day 78 (end of consolidation)
Correlation between peripheral blood cellular DNA MRD and bone marrow MRD
Pearson correlation coefficient between MRD measured in peripheral blood cellular DNA and MRD measured in bone marrow cellular DNA.
Time frame: At day 29
Correlation between peripheral blood cellular DNA MRD and bone marrow MRD
Pearson correlation coefficient between MRD measured in peripheral blood cellular DNA and MRD measured in bone marrow cellular DNA. At day 71 to 78
Time frame: At day 78
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 1
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 4
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 8
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 15
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At day 29
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up At day 71 to 78
Time frame: At day 78
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: At end of maintenance
Clonal evolution detected in cell-free DNA
Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up
Time frame: 3 years after remission
Concordance of genomic alterations between cfDNA and other biological compartments
Qualitative and quantitative comparison of genomic alterations detected at diagnosis in cfDNA and in other sample types (bone marrow, cerebrospinal fluid, and other tissues if available)
Time frame: At diagnosis
Prognostic value of cfDNA MRD
Association between cfDNA MRD levels and relapse-free survival and event-free survival
Time frame: Up to 5 years of follow-up
Fragmentome and methylome profiles of circulating DNA
Characterization and comparison of cfDNA fragment size patterns and methylation signatures between patients and healthy controls at diagnosis and during treatment. At baseline and during treatment
Time frame: Up to 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jul 2029, 39 months after the start.
Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 39 months is below that.
Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Assistance Publique - Hôpitaux de Paris →